Unicycive(US:UNCY)2025-08-14 12:15Financial Performance - Unicycive ended Q2 2025 with $22.3 million in cash, providing a runway into the second half of 2026[5] - Net loss attributable to common stockholders for Q2 2025 was $6.4 million, compared to a net income of $3.0 million in Q2 2024, largely due to changes in the fair value of warrant liability[10] - Other income for Q2 2025 was $0.5 million, a significant decrease from $17.3 million in Q2 2024, primarily due to changes in fair value of warrant liability[9] - Total operating expenses for Q2 2025 were $6.96 million, down from $7.40 million in Q2 2024[19] Research and Development - Research and Development (R&D) expenses decreased to $1.8 million in Q2 2025 from $4.9 million in Q2 2024, primarily due to reduced drug development costs[7] - Unicycive's second investigational treatment, UNI-494, has received orphan drug designation for preventing Delayed Graft Function in kidney transplant patients[12] Administrative Expenses - General and Administrative (G&A) expenses increased to $5.2 million in Q2 2025 from $2.5 million in Q2 2024, mainly due to higher consulting and professional services for commercial launch preparation[8] Regulatory and Clinical Updates - Unicycive has requested a Type A meeting with the FDA to resolve the Complete Response Letter (CRL) for OLC, typically granted within 30 days[6] - The company plans to provide an investor update in Q3 2025 following FDA feedback[6] - OLC pivotal study data published in CJASN showed over 90% of patients achieved effective phosphate control with a low pill burden[5]